Exanthema – Pipeline Review, H2 2011 by GlobalMarketsDirect

VIEWS: 4 PAGES: 26

More Info
									Exanthema – Pipeline Review, H2 2011




                          Exanthema – Pipeline Review, H2 2011


                                                                                          Reference Code: GMDHC1619IDB
                                                                                          Publication Date: December 2011




Exanthema – Pipeline Review, H2 2011                                                      GMDHC1619IDB / Pub December 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                            Page(1)
Exanthema – Pipeline Review, H2 2011




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 3
    List of Figures ................................................................................................................................................................................ 3
Introduction......................................................................................................................................................................................... 4
    Global Markets Direct Report Coverage ........................................................................................................................................ 4
Exanthema Overview ......................................................................................................................................................................... 5
Therapeutics Development................................................................................................................................................................. 6
    An Overview of Pipeline Products for Exanthema ......................................................................................................................... 6
Exanthema Therapeutics under Investigation by Universities/Institutes ............................................................................................. 8
Late Stage Products ........................................................................................................................................................................... 9
    Comparative Analysis .................................................................................................................................................................... 9
Mid Clinical Stage Products.............................................................................................................................................................. 10
    Comparative Analysis .................................................................................................................................................................. 10
Exanthema Therapeutics – Products under Investigation by Universities/Institutes ......................................................................... 11
Exanthema – Therapeutics Assessment .......................................................................................................................................... 12
    Assessment by Monotherapy Products ....................................................................................................................................... 12
    Assessment by Route of Administration ...................................................................................................................................... 13
    Assessment by Molecule Type .................................................................................................................................................... 15
Drug Profiles..................................................................................................................................................................................... 17
    Bepanthen - Drug Profile ............................................................................................................................................................. 17
         Product Description................................................................................................................................................................. 17
         Mechanism of Action ............................................................................................................................................................... 17
         R&D Progress ......................................................................................................................................................................... 17
    Threolone - Drug Profile .............................................................................................................................................................. 18
         Product Description................................................................................................................................................................. 18
         Mechanism of Action ............................................................................................................................................................... 18
         R&D Progress ......................................................................................................................................................................... 18
    Synthomycine - Drug Profile ........................................................................................................................................................ 19
         Product Description................................................................................................................................................................. 19
         Mechanism of Action ............................................................................................................................................................... 19
         R&D Progress ......................................................................................................................................................................... 19
    Urea 40% Cream - Drug Profile ................................................................................................................................................... 20
         Product Description................................................................................................................................................................. 20
         Mechanism of Action ............................................................................................................................................................... 20
         R&D Progress ...................................................................
								
To top